• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Rational design of nanocarriers for mitochondria-targeted drug delivery

    2022-09-15 03:10:46LihuHungZonghoSunQinShenZhongxiHungShungxiWngNidiYngGongqingLiQiongWuWeiWngLinLiChngminYu
    Chinese Chemical Letters 2022年9期

    Lihu Hung, Zongho Sun, Qin Shen, Zhongxi Hung, Shungxi Wng, Nidi Yng,Gongqing Li, Qiong Wu,?, Wei Wng, Lin Li, Chngmin Yu,c,??

    a Key Laboratory of Flexible Electronics (KLOFE) & Institute of Advanced Materials (IAM), Nanjing Tech University, Nanjing 211816, China

    b Institute of Agro-product Safety and Nutrition, Zhejiang Academy of Agricultural Sciences, Hangzhou 310021, China

    c State Key Laboratory of Coordination Chemistry, Nanjing University, Nanjing 210023, China

    ABSTRACT Well-developed mitochondria-targeted nanocarriers for function regulation are highly desirable.Numerous studies have been conducted on the treatment of mitochondria-related diseases; however, further improvements are required to develop more effective drug delivery methods.Herein, we comprehensively introduce recent developments progress in rational design of mitochondria-targeted nanocarriers,and discuss the different strategies of available nanocarriers for targeting mitochondria.We also highlight the advantages and disadvantages of various carrier systems that are currently in use.Finally, perspective on new generation for mitochondria-targeted delivery systems in the emerging area of drug-based therapeutics is also discussed.

    Keywords:Mitochondria target Mitochondria diseases Therapeutic drugs Nanocarriers

    1.Introduction

    The mitochondrion is one of the most well studied organelles.It is a double-membrane-bound organelle that is possessed in almost all eukaryotic cells and consist of four parts, namely the mitochondrial outer membrane, inner membrane, interstitial membrane, and mitochondrial matrix.The inner membrane of mitochondria folds inwards to form mitochondrial crest, which is responsible for many biochemical reactions [1].Mitochondria are small but extremely powerful, which is the main production site of oxidative phosphorylation and synthesis of adenosine triphosphate (ATP) in cells, providing energy for cell life activities, known as the factory of capacity.Mitochondrial activity is essential for all mammalian tissues and for most cell types (excluding red blood cells) [1,2].In addition to supplying energy to cells, mitochondria are involved in processes such as cell differentiation, cell messaging and apoptosis, and have the ability to regulate cell growth and cell cycle [3].Mitochondria also play a central role in intermediate metabolism, synthesis of key iron-sulfur cluster enzymes, cellular calcium homeostasis, and cell death through apoptosis.In addition to water, mitochondria are composed of nucleic acids, proteins and lipids, which play an important role in cells.The disorder of genetic factors controlling mitochondrial gene replication and transcription can lead to the generation of disease factors or even death of the body [4,5].If the mitochondrial electron transport chain does not capture electrons correctly, the escaped electrons will combine with oxygen molecules to generate superoxide free radicals, which can easily destroy the mitochondrial DNA (mtDNA) bases and cause mtDNA mutations, and then accumulate some aging or disease factors of cells, such as diabetes, heart disease, arthritis [6–9].In addition, these superoxide radicals activate inflammation, causing damage to other tissues in the body [10–15].Differences between the mitochondria in normal cells and cancer cells include a number of functional changes,such as mtDNA mutations that cause oxidative phosphorylation inhibition, nutrient hypoxia or depletion.Specially, changes in mitochondrial metabolism in cancer cells are conducive for selective targeted treatment of mitochondria.These treatments are mainly aimed at the specific characteristics of the mitochondria found in cancer cells.Therapeutic drugs that specifically target mitochondria are an effective treatment method for diseases.For this reason,engineered therapeutics targeting the mitochondria are viewed as potential disease treatment strategies.

    Therefore, mitochondria play an important role in cell growth and development.Differences in mitochondria between normal and abnormal cells include many functional changes.The change of mitochondrial metabolism is conducive to selective targeted therapy of mitochondria.In recent years, many therapeutic drugs and targeting systems for mitochondrial diseases have been developed,making important contributions to clinical research on the diagnosis and treatment of mitochondrial diseases.Herein, we provide a comprehensive review of recent advances in the rational design of mitochondrial targeting nanocarriers and discuss the different strategies available for mitochondrial targeting nanocarriers.We also highlight the advantages and disadvantages of the various carrier systems currently in use.Finally, the application prospect of a new generation of mitochondrial targeted drug delivery system in the field of drug therapy is prospected.We hope that this review will offer a comprehensive understanding of the importance of mitochondrial targeting drug delivery systems and facilitate the development of more effective mitochondrial targeting systems.

    2.Current therapeutic drugs for mitochondrial diseases

    Current therapeutic drugs for mitochondrial diseases include active proteins, genes, and small-molecule drugs,etc.Protein- and peptide-based drugs usually have specific three-dimensional structures and sites of action, which can exert specific therapeutic effects in the body.Proteins are suitable for use as a sustainable controlled release formulation [16].The advantages of sustainedrelease protein delivery formulations include its suitability for long-term treatment, use for local delivery, fewer side effects, less doses than traditional drugs, reduced dosing frequency, and improved patient compliance.They have better clinical effectiveness and safety compared to traditional drugs.However, when these drugs enter the body, most of them have problems such as poor stability, poor circulation, low bioavailability, short half-lifein vivo,and easy to be degraded by enzymes in the body.In particular,protein and peptide drugs that are employed to treat chronic diseases often require long-term and frequent injections, which not only result in low treatment efficiency, but may cause other adverse reactions.Therefore, the pharmaceutical industry continues to carry out research to improve the performance of protein and peptide drugs, such as the modification of hydrophilic polymers on proteins to enhance the water solubility of protein drugs, which provides the basis for the application of most protein drugsin vivo.The modified protein drug has increased molecular weight and avoids glomerular filtration.Meanwhile, the hydrophilic polymer blocks reticulo-eneophagocytic system (RES), which exists widely in liver, spleen and lymph nodes, and provides a good protection for the protein drug.The protective effect of hydrophilic polymers also prevents the degradation of enzymes in the body.What is more, the chemical bonds between the drug and the polymer slowly hydrolyze over time, which facilitates the release of the protein drug [16–18].The ideal protein delivery formulation should have the function of controlled release, maintain the therapeutic level and ensure the stability of the encapsulated protein during the prolonged drug action time.The components of the delivery system must be biodegradable and biocompatible, nonimmunogenic, and non-toxic.At the same time, the structure and activity of the protein drug must not be changed during the preparation of the delivery system, and the protein must assume an active conformation after being released in the body.On top of all these factors, the preparation method for protein intracellular delivery should have scalability, durability and reproducibility.In fact, the use of carriers to deliver encapsulated proteins to target organelles such as mitochondria is one of the current research hotspots.

    Another therapeutic for mitochondrial diseases is gene-based drugs.Gene-based therapies can effectively regulate both coding and non-coding target genes with high specificity, and have broad application prospects in the treatment of various human diseases[19–21].Biotech and pharmaceutical companies are working hard to develop many gene therapy drugs.Gene therapy drugs are also biomedical products that are administered in the form of nucleic acids, viruses, genetically engineered microorganisms, or lipid complexes to achieve preventive, diagnostic and therapeutic effects[22].The approach of gene therapy represents the latest advance in the revolution in biomedical technology.In the past half century, gene therapy has rapidly absorbed almost all the advanced biotechnology, and many promising human gene therapy drugs have been developed.Since the end of the last century, a variety of gene therapy drugs, including cell-mediated gene therapy products, viral vectors, non-viral vectors and naked nucleic acids, have been approved by the US Food and Drug Administration (FDA) for the treatment of human diseases [22].One current approach for gene therapy involves cloning DNA sequences that encode genes associated with mitochondrial-targeting signals.The resulting recombinant genes are expressed as proteins once they are delivered to the cell.Thereafter, the protein is directed to mitochondrion by the mitochondrial targeting signal (MTS).The MTS enters cells through mitochondrial import mechanisms [23–27].The advantages of combining gene therapy vectors with encoded MTS include not only the ease of cloning of recombinant DNA, but also the advantage that these constructs can be prepared without chemical modifications.Although the prospect of gene drugs is promising, there are still many problems should be solved, such as safety, transmissibility, selectivity, stability, immunity.Therefore,the development of the nucleic acid drugs and their safe and effi-cient delivery system are the key challenges in the clinical application of gene therapy.

    In the last few years, several new candidate drugs have been assessed and developed for various diseases.Among them, the structure of small-molecule drugs has good spatial dispersion, and its chemical properties determine its good drug-making properties and pharmacokinetic properties.These characteristics make small molecule drugs show great advantages in the drug development process and other drug fields, and the research and development of small molecule drugs is increasingly favored by the market.

    Meanwhile, small-molecule compounds derived from natural products have been demonstrated to display good preventive and treatment effects due to their antioxidant, anti-inflammatory, and neuroprotective functions [28,29].However, small molecule drugs,especially anti-tumor drugs, often have problems such as off target, low solubility, high toxicity, rapid excretion or unstable biological distribution.At the same time, most natural small molecule drugs have inherent disadvantages such as short half-life, poor stabilityin vivo, easy to be cleared, which make it difficult for small molecule drugs to accumulate effectively at the target site [28–30].At present, researchers use nanoparticles as drug delivery carriers, which can effectively improve the water solubility of small molecule drugs, thereby reducing the drug dose and cytotoxicity.The drug can be delivered to the lesion to improve the efficacy.It also plays an important role in reducing clearance and increasing drug retention time in the body [31].

    Actually, by targeting mitochondria delivery, some of disadvantages for the therapeutic drugs have been solved recently.Until now, their application in various targeted therapies, such as targeted therapies for cancer, neurodegenerative diseases, autoimmune diseases, and several other diseases, has been reported[32,33].The development of mitochondria-targeted drug therapy in the pharmaceutical industry is growing.In subsequent sections,we introduce of mitochondria-targeted moieties and present delivery strategies for achieving targeted delivery to the mitochondria,with focusing on rationally designed routes, related mechanisms,and the potential therapeutics.

    3.Mitochondria-targeted moieties

    Since mitochondria are considered as emerging pharmacological targets, there are currently several targeted therapeutic strategies for mitochondria-related diseases.Based on the characteristics of the mitochondrial membrane, numerous of mitochondriatargeted moieties have been developed for enhancing the mitochondrial uptake (Fig.1) [34–55].

    Fig.1.The three kinds of mitochondria-targeted moieties designed for enhancing the mitochondrial uptake.

    3.1.Small molecule moieties

    Drugs that regulate mitochondrial function to achieve certain diagnostic or therapeutic effects can be used for mitochondrial targeting, but a series of problems such as the feasibility of drug delivery, drug toxicity and biocompatibility need to be considered.In order to solve the above problem, designing a series of mitochondrial targeted nanocarriers based on small molecule moieties is developed by using the high negative potential of the properties in the mitochondria membrane.The negative potential of plasma membrane size is only 30–40 mV, while mitochondrial membrane negative potential can reach 120–180 mV, significantly less than the plasma membrane potential, making the Coulomb force between the positively charged compounds and mitochondrial membrane greater than that of other negatively charged membrane.They are more likely to accumulate in the mitochondria.For example, the enrichment amount or concentration of triphenylphosphine (TPP) cationic compounds in mitochondria is 20-300 times higher than that in plasma membrane, achieving highly specific targeting of mitochondria [7,34].However, some lipophilic cations have phototoxicity and poor water solubility, leading to poor circulationin vivoand reducing their efficacy.The mitochondrial targeting section of the widely studied TPP ion derivative takes advantage of its strong lipophilicity and the properties of delocalized cationic to target inner mitochondrial membrane (IMM).The negative membrane potential of IMM is the key to driving lipophilic cations to target mitochondria.Therefore, in addition to TPP cation derivatives, aromatic heterocyclic cation derivatives such as pyridine cation and quinoline also have mitochondrial targeting ability[47,53].Dequalinium (DQA) is a small positively charged molecule containing two cationic amino quinoline rings, which are attracted to the IMM through electrostatic interaction and selectively accumulate in the mitochondria-cartilage matrix [47].Under physiological conditions, guanidine or bisguanidine are strong bases(pKa~13) with a positive charge delocalization.When guanidine or bisguanidine groups are partially coupled to the target pharmacokinetic molecule as mitochondrial targets, a delocalized positive charge is introduced to increase lipophilicity, thus concentrating the target molecule in the IMM [48,49].Rhodamine contains three benzene rings in the form of spironolactone in a nonpolar solvent [50].In a polar solution, it changes from the lactone form to a zwitter ion and exists in the form of ammonium cation in the ring-open state.Due to the negative potential of IMM, rhodamine is able to specifically target mitochondria in the form of ammonium cations.Tetramethylrhodamine-5-isothiocyanate (TRITC) is another hydrophilic derivative of rhodamine which is often used as a fluorescent probe to target mitochondria [51,52].Based on the lipophilic and cationic properties, pyridine salts structures show the ability to target mitochondria [53].Berberine (BBR), an isoquinoline alkaloid, has many outstanding pharmacological effects.Because anthocyanin dyes are cationic and lipophilic, they can accumulate in the mitochondria as well [40,41].Herein, the currently reported small molecule moieties are summarized in Table S1 (Supporting information).According to the properties of mitochondrial membrane, we believe more and more small molecules moieties will be designed for mitochondrial targeting.

    3.2.Peptide/protein moieties

    As summarized in Table S2 (Supporting information), another strategy for targeting mitochondrial involves using peptides/proteins moieties, which have specific physical and chemical properties.Similar to lipophile cations, mitochondria-targeted peptides (MTP) is an effective alternative to lipophile cations and can target bioactive substances to the mitochondria.The synthetic MTP contains hydrophobic amino acids (tyrosine, phenylalanine,and isoleucine) which can penetrate the lipid membrane and positively charged amino acids (lysine and arginine) by binding to the negatively charged mitochondrial membrane through electrostatic interactions [53–55].Currently, most synthetic MTP structures contain positively charged amino acids (arginine and lysine) in order to concentrate on the negatively charged IMMs.The MTPs are firstly recognized by the outer mitochondrial membrane (OMM)once they attach to the pharmacophore.They then enter the mitochondrial matrixviaOMM, thereby achieving mitochondrial targeting capabilities.At present, the most commonly used MTP mainly include pro-apoptotic peptide (KLAKLAK)2, biologically active peptide sequence (rFxrFxrFxr), and the trans-activating transcriptional activator (TAT).(KLAKLAK)2is a kind of cationic amphiphilic peptides which haveα-helix configuration [53].It has been reported that KLA is a pro-apoptotic peptide, which can enrich mitochondria, destroy the negatively charged mitochondrial membrane and induce cell apoptosis.The bioactive peptide sequence rFxrFxrFxr possesses D-arginine and mitochondrial targeting ability [56].The arginine-rich cell-penetrating peptide, TAT (YGRKKRRQRRR) acts as a mitochondrial targeting element that targets molecules and localizes in mitochondria [57–63].Another mitochondrial penetrating peptide, namely mitochondrial localization sequences (MLSs),usually consists of 20–30 amino acids (detailed sequences in Table S2) [64–81].MLSs can be recognized by mitochondrial surface receptors, and the targeting sequences are variable in length and amino acid sequence.Their main characteristics are the presence of positively charged residues, the lack of acidic residues, and the formation of amphiphilic secondary structure.Mitochondrial targeted receptor proteins form a protein family, including the translocases of outer membrane (TOM) and the translocases of inner membrane(TIM) [53,63].Protein targeting sequence has good biocompatibility, but false positive may occur, which may target to other locations other than mitochondria, resulting in false positive signals.The protein sequence is eliminated too quickly in the body to be effective.To solve this problem, some positively charged amino acids can be linked to targeted protein sequences to increase the efficiency of mitochondrial targeting.

    3.3.Other moieties

    Amphiphilic modifications are often carried out on nanoparticles to make it easier for lipophilic substances to pass through the lipid components of mitochondrial membrane.Amphiphilic polymers provide chemically reactive groups for post-modification of polymer nanomaterials with targeting ligands (such as antibodies and peptides) to specifically target cell sites (such as membrane receptors and organelles) [82].Chitosan and chitosan-based nanoparticles, which are examples of polymers, have a number of unique properties, including low toxicity, biocompatibility, biodegradability, and the capacity for mucoadhesion.Chitosan is a positivelycharged polycationic biological macromolecule that can be developed as mitochondrial drug delivery systems for mitochondria[9,83,84].

    In addition to polymers moieties, there are other types of targeted modification groups, such as aptamers, transition metal complexes, which are summarized in Table S3 (Supporting information).Aptamer, which is a single-stranded DNA or RNA (ssDNA or ssRNA), has a unique tertiary structure that can specifically bind to homologous molecular targets.Aptamers are usually screened through systematic evolution of ligands by exponential enrichment [85,86], targeting from small molecules [87,88] to biomacromolecules [86,89–94], infected cells, stem cells, and tumor tissues[95–104].Aptamers can be used as therapeutics by themselves.They have been extensively studied as targeting ligands such as for mitochondria.The programmability of aptamers and the ease of synthesis and modification allow them to be universally used as targeted ligands for drug delivery [105–108].Previous studies have reported that many Ir(III) complexes have a positive charge and can specifically target mitochondria without modification of the mitochondrial-targeting units [39].In addition, some natural substances or designed molecular substances can interact with the mitochondrial respiratory chain complex to generate a large number of reactive oxygen species (ROS) and oxidized endogenous pyridine nucleotides, triggering the opening of mitochondrial permeability pores (MPTP).Glycyrrhizic acid (GA), an extract from licorice, is a mitochondrial targeting ligand with a near-neutral charge [28].GA can interact with the mitochondrial respiratory chain complex to produce large amounts of hydrogen peroxide and oxidize endogenous pyridine nucleotides, triggering MPTP to open.The drug then moves inside the mitochondria to react.Kong’s group found hypericin (HY) is an effective ligand to target mitochondria [29].Under laser irradiation, HY interacts with mitochondrial respiratory chain to produce singlet oxygen.The generated singlet oxygen then oxidizes critical thiol groups and endogenous pyridine nucleotides,resulting in the opening of mitochondrial permeability transition pores, then the drug goes into the mitochondria, which is a common mechanism of action for various mitochondrial-targeting ligands [109,110].

    4.Nanoparticle-mediated delivery systems

    A wide array of nanocarriers have been identified as promising strategies for organelle-targeted delivery.In these strategies,the delivery systems could be engineered with various ligands for targeting to the desired subcellular compartments like cytosol, nucleus and mitochondria [111–118].Moreover, recent studies have reported that engineered nanocarriers can be combined with integration of stimuli triggers to allow for drug delivery with both dosage-dependent and spatiotemporal-controlled manners possible, facilitating release of drug with desirable pharmacokinetics [119].Until now, numerous synthetic nanosystems have been designed and developed for mitochondria-targeted drug delivery [120–124].

    4.1.Liposome

    Due to their relative safety and simplicity, lipid-based nanoparticles have been widely used in systemic delivery nanocarriers.The liposome carrier can transport water-soluble drugs in its core or fat-soluble compounds in its outer membrane layer.Compared with chemically-modified drugs, this delivery method encapsulates active molecules without altering their molecular structure,thereby maintaining the pharmacy dynamic characteristics of the drug.This type of delivery system protects the loaded drug from biodegradation or chemical degradation in the blood, and releases drugs at the target site in a suitable manner [125].In current clinical trials with mice and humans, liposome drug delivery systems have been used for targeted delivery of a variety of anticancer drugs, including biomacromolecules and hydrophobic drugs[62,125–147].Some liposomes, such as liposomal adriamycin and liposomal paclitaxel have been approved by FDA and are widely used in the treatment of metastatic ovarian cancer, breast cancer.This delivery system also significantly reduces toxicity of the drugs in the patient’s heart [125,127–139].To prevent the enrichment of liposomal nanoparticles in the organism, which makes their degradation difficult, their surface generally modified with a little hydrophilic group to improve their biocompatibility.Chemical modifications on liposome can enable their effective entry into mitochondria.For example, Harashima’s team described a liposome carrier that delivered a macromolecular cargo to the interior of the mitochondriaviamembrane fusion [137].As shown in Fig.2,these liposomes, called MITO-Porters, were modified with octaarginine (R8) moieties on their surfaces as a complete vesicle MITOPorter.Amino acid polymers and synthetic arginine peptide analogues have been reported to be as the translocation domains to improve cargo delivery efficiency [140–142].As shown in Fig.2A,MITO-Porter entered the cell through endocytosis, was degraded by lysosomes, and banded to mitochondria through electrostatic interaction.The results showed that nanocarriers containing R8 have better fusion efficiency than those without R8, indicating that the strong electrostatic binding between R8-based liposomes and mitochondria stimulates.The delivery model of this experiment was green fluorescent protein, and western blot showed that it had a good delivery effect.This provides guidance for the mitochondria targeted drug delivery of biomacromolecules.The MITOPorters can be employed to transport functional nucleic acids, proteins, and small biologically active molecules.Such delivery systems are very promising as they can transport molecules with different physicochemical characteristics as well as large or small encapsulated molecules.Cationic liposomes are considered to be another promising nanocarriers for improving mitochondrial delivery.For example, Taillandier’s team used trimethyl aminoethane carbamoyl cholesterol iodide (TMAEC-Chol) and dioleoyl phosphatidylethanolamine (DOPE) to create a liposome with clear size and stability [143].In order to further transfer the oligonucleotide into the mitochondrial matrix, the oligonucleotide was linked to the ornithine transcarbamylase signal peptide, which is recognized by the mitochondrial protein import mechanism and then enters the mitochondria.Therefore, suitable cationic liposomes and peptide oligonucleotide conjugates can be used in mitochondrial gene therapy experiments, which lays a foundation for the treatment of mtDNA abnormal diseases [144,145].Deng’s group postulated that mitochondrial targeting and stimuli-triggered liposome delivery system could be employed to derive new therapies for deep tumor treatment [135].Liposomes were connected to TPP with verteporfin and gold nanoparticles being encapsulated inside the liposomes.Low-dose X-rays can trigger verteporfin to produce cytotoxic ROS.In this process, porphyrin transferred the absorbed energy to oxygen to form a highly active single oxygen with a shortterm maintenance time.Single oxygen destroyed various biological structures within its diffusion range.This process leaded to local vascular atresia, cell destruction, and cell death under certain circumstances.Co-encapsulation of gold nanoparticles (10 nm) in the central core of liposomes can increase the production of ROS for deep tumor treatment.

    Fig.2.(A) Mechanism of the transport of macromolecules to the mitochondria using MITO-Porter.(B) R8-LPS (a fusion lipid commonly used for drug delivery) composed of DOPE (R8DOP-LPS) shows higher fusion activity than R8-LPS (R8-EPC-LPS) composed of egg yolk phosphatidyl choline.(C) The purified GFP was incubated with the IMS portion or IB portion, and Western blotting showed that the molecular weight of GFP was 28 kDa when incubated in IMS, but remained intact when incubated in IB, thus proving that Mito-Porter delivered GFP to IMS via OM.Reproduced with permission [137].Copyright 2018, Elsevier.

    In conclusion, lipid-based nanoparticle delivery systems for mitochondria have been extremely studied owing to their promising features.However, some limitations, such as the high cost of raw material, easy accumulation in the phagocytes are still the main issues for this strategy [146,147].Thus, other alternative materials are needed for specific disease, as well as offer unique advantages.

    4.2.Polymer nanosystem

    Owing to their simple preparation method and easy modification, high-molecular-weight, diverse polymeric delivery systems have been extensively used for drug delivery and achieved excellent performance.Especially, through modifying with mitochondria targeted moieties, the polymer-based nanocarriers such as polyethylene glycol (PEG), polycaprolactone (PCL), and chitosan have been designed for the treatment of mitochondria related disease [9,67,148–181].For example, Du’s group reported an innovative mitochondria targeted prodrug nanocarrier characterized by pH-triggered and aggregation-induced emission (AIE) properties(Fig.3) [154].In this work, the nanocarrier was constructed by surface-modification of the TPP group with polyurethane (PU).Colocalization studies of mitochondrial pairs showed that this modification can improve the targeting of organelles.A zwitterionic shell was then attached, which can prolong the blood circulation and accumulate at the tumor site.The ketal bond of the nanomicelles enabled controlled release of therapeutically significant molecules.In addition, the addition of luminogen tetraphenylethene (TPE) based on AIE was allowed to realize labelling and monitoring of the mitochondria of living cells in real time.The model drug cinnamaldehyde induced ROS production in tumor cells to promote oxidative stress and activate apoptosis pathways.Moreover, this nanocarrier has been proven to have many advantages in cell imaging, including good AIE properties, anti-photo-bleaching and low cytotoxicity, which provide a feasible strategy for simultaneous cancer diagnosis and treatment.In summary, this prodrug nanocarrier not only has mitochondrial targeting function but also can kill cancer cells and monitor the process of apoptosis in real time.Meantime,Chen’s team created a polymer-based nanoparticle based on TPPpoly(ethylene glycol)-poly(ε-caprolactone) (TPP-PEG-PCL) polymers that enhanced mitochondrial targeting with TPP [155].Gambogic acid was used as model drug to treat lung cancer.Due to poor water solubility (~10 μg/mL) and short half-life (15.7 min), the low bioavailability of gambogic acid limits its clinical application[9].The limitation of gambogic acid was overcome when the polymer nanomicelles were formed.After the gambogic acid was transferred into mitochondria, it can induce apoptosis of cancer cells by inhibiting human Bcl-2 family proteins and activating cystease.Recently, Choi’s team created an amphiphilic polymer nanomicelle using glycol-chitosan and DQA [9].In this nanosystem, ethylene glycol chitosan (GC) was used to enhancein vivocirculation and DQA served as mitochondrial targeting and wrap around the anticancer drug curcumin for cancer treatment studies.The molecular structure of curcumin has phenolic hydroxyl groups, which can capture or clear free radicals and have antioxidant effects[10].Zhanget al.found that curcumin could inhibit the expression of COX-2 mRNA and prevent the occurrence of tumor [11].The defects of fast metabolism and short half-life of curcumin were ameliorated by targeting mitochondria delivery.The experiment showed that this nanosystem had the great potential of mitochondrial targeted drug delivery for cancer treatment.

    Fig.3.(A) Mechanism of the pH-triggered prodrug.(B) In order to observe the AIE properties of nanocarriers, the fluorescence changes of prodrug polymer in DMSO/water system were studied.The experiment showed that the fluorescence gradually increased with the increase of water content, indicating the desire to be aggregates.(C) The results of experiment results proved that the pH-responsive drugs of TPE-CB-CA-TPP were beneficial to the effective release of intracellular drugs.Reproduced with permission [154].Copyright 2019, The Royal Society of Chemistry.

    Due to the good biodegradability and biocompatibility, numerous polymers, specially the synthetic polymers can be referred as biomaterials to produce nanoformulations for mitochondriatargeted delivery.However, owing to the complexity of polymerbased nanocarriers with multicomponent 3D structures, careful designing and construction are needed to make sure reproducible formulations in the large-scale manufacturing processes [79,181].Furthermore, the smart polymers with multifunction, multicomponent and controlled release on demand in mitochondria and high effi-cient diffusion of therapeutic drugs through a stimulus property of the disease microenvironment are urgently needed.

    4.3.Inorganic nanosystem

    With the development of nanotechnology in recent years, inorganic nanocarriers with unique biological, chemical, and physical properties have become increasingly prominent in biomedicine.Inorganic nanocarriers are utilized not only as diagnostic reagents,but also for the prevention and treatment of certain medical conditions such as tumor, cardiovascular diseases and neurodegenerative diseases.Presently, an increasing number of inorganic nanomedicine carriers have been employed as targeted therapies for specific tumors.Accordingly, they have gradually become a research focus in the medical field [182–203].

    Due to the biocompatibility and tunable pore size, mesoporous silica nanoparticles (MSNs) have been applied for storage and delivery of drugs [199].Jung’s team firstly conjugated guanidinium derivative to MSN shell with Fe3O4core and then coated it with the anti-tumor drug doxorubicin (DOX) to achieve mitochondrial targeted tumor therapy [182].DOX blocks DNA synthesis by inserting DNA strands, and its toxicity to topoisomerase also inhibits DNA synthesis.DNA damage leads to activation of p53 tumor suppressor gene, aggregation of related proteins, and mitochondrial dysfunction, which are a series of events in the early stage of cell death.DOX also induces the production of free radicals and accelerates the induction of tumor cell death.Jung’s experimental results showed that the nanosystem could localize in mitochondria and release DOX on demand, which accelerated the induction of tumor cell death.

    Current methods for mitochondria targeting are feasible for small-molecule drugs, while many methods are not suitable for large drugs, such as proteins (including antibodies).The first example of using biodegradable silica nanoparticles (BS-NPs) to target mitochondria for intracellular delivery of native proteins (and antibodies) was reported by Yao’s team (Fig.4) [184].In this work,the synthesized biosilica nanoparticles were modified with cellpenetrating poly(disulfide) (CPD) that allowed nanoparticles to enter cells, and TPP drives for targeting mitochondria.In the presence of glutathione (GSH), CPD was degraded and TPP was exposed, and then the BS-NPs could enter into the mitochondria for the protein releasing.The experimental results provided reference for the delivery of macromolecules into mitochondria.

    Fig.4.(A) Preparation and application of cell-permeable CPD-TPP-protein@BS-NP.(B) HeLa cells were incubated with CPD-TPP-RBBSA@BS-NP.The results showed that after cultured for 24 h, most BS-NPs were located in the mitochondria (white circles denote mitochondria, arrows denote BS-NPS), and degraded after 72 h.(C) To monitor the release of BSA on the nanocarrier, the supernatant of GSH-treated FLBSA@BS-NPs was collected periodically between 0 and 72 h for fluorescence measurements.The experiment showed that the nanocarrier encapsulated BSA was successfully released.Reproduced with permission [184].Copyright 2019, Wiley.

    Various inorganic nanoparticle-mediated delivery systems have been studied for mitochondria targeted delivery of drugs.Unlike the lipid-based nanoparticles, these inorganic nanoparticles are considered to be easier during manufacturing.The stability of the inorganic nanoparticles enables them to remain in long-term circulation in the body, however, this also makes them difficulty to be decomposed and cleared from body, leading to the accumulation in the liver, lungs and kidney [200].Therefore, development of the biodegradable inorganic nanoparticle-based system is an effective way to solve this issue.

    4.4.Peptide/protein system

    Due to peptide/protein-based NPs have the advantages of high bioavailability, good solubility, low toxicity, and good targeting ability, they have been developed as one of the most promising nanomaterials.In addition, the peptide-based backbone exhibits the following advantages: easy synthesis, high tunability,good biocompatibility, and high absorbability in cells orin vivo.Due to their simple and modular synthesis, peptides that target the mitochondria can adapt to different delivery conditions.The main design features of peptides targeting the mitochondria are cationic charge and lipophilicity.Cationic charge enables the peptides to fully utilize the negative mitochondrial membrane potential while lipophilicity enables them to interact well with the hydrophobic membrane of the mitochondria.As carriers, peptides are covalently linked to therapeutic drugs to enhance their drug value and unravel a pathway for the study of mitochondrial biology [31,57,62,151,194,204–215].

    Recently, Rapaport’s team synthesized a polypeptide-peptide nanoparticles (Pop-NPs) with an amphiphilic and cationicβ-sheet peptide (PFK) drive [133,205].After complexed with siRNAsviacharge interaction, the nanosystem could deliver oligonucleotide cargos to mitochondria, which provided guidance for the delivery of nucleic acid drugs.

    Protein-based delivery platforms show exciting ways of significantly improving therapeutic effect and reducing adverse reactions in the body [214].Until now, a number of proteins have been developed for use substrates in protein-based nanoparticles for drugs delivery, such as gelatin, albumin, collagen, whey proteins, casein,gliadin, elastin, silk proteins, soy proteins, and lectins [215].Lin’s team discovered a new self-assembled metalloprotein nanoparticle, GST-MT-3 (Fig.5).Here, metallothionein-3 (MT-3) can regulate zinc ion homeostasis and control cell proliferation and differentiation by influencing mRNA production [194].The nanoparticles were linked to mitochondrial transport peptides GST for mitochondrial targeting.After further chelating cobalt ions [GST-MT-3(Co2+)], this nanosystem could induce ROS production and reduce the mitochondrial membrane potential.In addition, GST-MT-3 covalently bonded to paclitaxel could furhter inhibit tumor growth.The in cell andin vivoresults showed that the nanoparticles could rapidly assemble in tumors and target mitochondria, inducing ROS production and tumor cell death through the apoptotic pathway.

    Fig.5.(A) Illustration mechanism of the novel GST-MT-3 protein nanoparticle.(B) GST-MT-3(Co2+) was rapidly internalized by HeLa and U87MG cells and localized in mitochondria.(C) The mitochondrial membrane potential of HeLa cells decreased after treatment with GST-MT-3-CY5.5 analogues for 24 h.Reproduced with permission[194].Copyright 2019, Wiley.

    Protein-based delivery platforms for targeting mitochondria display exciting ways to significantly improve drug delivery and therapeutic effects.The efficacy of protein-based nanoparticles can be increased by combining these nanoparticles with other FDAapproved treatments.While the progress is still needed to develop the potential in the improvement and mechanistic understanding,as well as the feasibility of using protein-based nanoparticles and their derivative in combination therapy in the clinical field of tumor treatmentin vivo.

    4.5.Other delivery systems

    Apart from the above nanocarriers employed to transport biologically active molecules into the mitochondria, there is increasing interest in the use of other systems in the delivery of various drugs into mitochondria [34,46,105,133,146,163,197,216–280].For example, metal-organic frameworks (MOFs) in particular have arisen in the last years as favorable candidates for nanomedicine applications, owing to their unique properties [217–223].To date, a number of therapeutic drugs have been encapsulated in MOFs, including anticancer, antibacterial, and antiviral drugs, as well as nucleic acids and biological gases [224].Recently, Jimenez’s group reported a novel mitochondria-targeted MOF-based nanosystem that greatly increased the efficacy of a model cancer drug [234].A Zr-MOF loaded with the cancer drug dichloroacetate (DCA) and conjugated with TPP for localizing to mitochondria was constructed.Whole transcriptome analysis of cells indicated wide spread changes in gene expression and profound effect on cell physiology and that are related to cell death.They showed that targeting MOFs toward mitochondria represents a valuable strategy for the development of new drug delivery systems.

    Different from the introduction of mitochondria targeted moieties, Lin’s group has synthesized a nano-MOF for mitochondriatargeted radiation therapy for tumors [235].In this work, the MOFs with surface modification of cationic ruthenium (Ru) can directly target mitochondria.In this way, targeting delivery with photosensitizers can effectively produce ROS, depolarize mitochondrial membrane potential, and lead to programmed cell death of tumor cells (Fig.6).

    Fig.6.(A) Process schematic of the Hf-DBB-Ru.(B) Representative mitochondria co-localization images of Hf-DBA-R and Hf-DBB-Ru by CLSM.(C) In vivo anti-cancer efficacy of mitochondria-targeted RDT.Excised tumour weights on day 22.Reproduced with permission [235].Copyright 2018, Springer Nature.

    In addition, Kubiet al.also presented a class of amphiphilic cell-penetrating motifs (CPMs).Each of them was composed of four guanidine groups linked to one or two aromatic hydrophobic groups (naphthalene), which was used for targeting mitochondria.They could assemble into nanoparticlesviaa central scaffold (such as a benzene ring) [229].CPM transferred drug geldanamycin into cells and allowed them to accumulate in the mitochondrial stroma.The results showed that CPM was metabolically stable and had little toxicity to normal cells, and could be used to deliver therapeutic agents into the mitochondrial matrix to treat mitochondrial diseases.

    5.Conclusion and prospect

    In summary, various nanocarriers have been developed for mitochondria-target drug delivery and shown great promise for enabling the current and next generations of therapeutics.This review described the current progress of research on nanocarriers for mitochondria-targeted delivery.We herein classify and summarize the reports according to the type of nanocarriers, which is shown in Table S4 (Supporting information).The occurrence and development of many diseases are caused by mitochondrial dysfunction.The subcellular targeting strategy could achieve maximum therapeutic responsive as well as avoiding cytotoxic side effects of the drugs.As a result, drug therapies targeting mitochondria are highly desirable.

    To improve drug intracellular delivery and active targeting, especially for the organelle and subcellular drug targeting, the surface of nanocarriers could be incorporated with receptor targeting ligands (e.g., TPP, cationic peptides) to specifically bind with a receptor of the mitochondria membrane.Although multiple basic research studies have been conducted many basic researches on mitochondrial diseases, the design of effective delivery methods need to be further improved.Many challenges currently remain, such as the stability and water solubility issues for liposomes, low drug loading efficacy for the polymeric nanoparticles, and difficulty of being decomposed and cleared from the liver, lungs and kidneys for inorganic nanocarriers,etc.

    Different types of nanocarriers have been recognized to possess their own advantages and disadvantages.More mitochondria targeted moieties and interaction mechanisms should be investigated for continuous improvements of novel nanocarriers in high efficiency, high drug loading capacity, strong targeting ability, and low side effects.Future research should also focus on the discovery and design of safer and more efficient mitochondrial-specific nanomaterials.

    In conclusion, we believe the potential for drug delivery using mitochondria-targeted nanocarriers is tremendous.More and more novel material or delivery vehicles emerge and others will likely be uncovered through further scientific research.

    Declaration of competing interest

    The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

    Acknowledgments

    We gratefully acknowledge financial support from the National Key Research and Development Project (No.2020YFA0709900), the Key University Science Research Project of Jiangsu Province (No.19KJA520005), the National Natural Science Foundation of China(No.22077101), the Open Project Program of State Key Laboratory of Coordination Chemistry (No.202008).

    Supplementary materials

    Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.cclet.2022.02.047.

    成年版毛片免费区| 久久久久久久精品吃奶| 给我免费播放毛片高清在线观看| 亚洲第一青青草原| 动漫黄色视频在线观看| 女人爽到高潮嗷嗷叫在线视频| 怎么达到女性高潮| 欧美国产日韩亚洲一区| 亚洲人成电影观看| 18禁美女被吸乳视频| 亚洲精品美女久久av网站| 一区二区日韩欧美中文字幕| 欧美日本亚洲视频在线播放| 免费在线观看视频国产中文字幕亚洲| 婷婷丁香在线五月| 免费在线观看黄色视频的| 国产亚洲av嫩草精品影院| 日韩三级视频一区二区三区| 亚洲av成人不卡在线观看播放网| 咕卡用的链子| 校园春色视频在线观看| 免费不卡黄色视频| av超薄肉色丝袜交足视频| 免费高清在线观看日韩| 黄片小视频在线播放| 男女下面进入的视频免费午夜 | 精品免费久久久久久久清纯| 国产91精品成人一区二区三区| 午夜福利18| 一边摸一边做爽爽视频免费| 手机成人av网站| 欧美乱码精品一区二区三区| 亚洲精品国产色婷婷电影| 免费在线观看亚洲国产| 国产av精品麻豆| 一二三四社区在线视频社区8| 日本 av在线| 免费无遮挡裸体视频| 91大片在线观看| 久久香蕉激情| 叶爱在线成人免费视频播放| 最近最新中文字幕大全免费视频| 日韩欧美一区二区三区在线观看| 国产精品久久久久久亚洲av鲁大| 搞女人的毛片| 国产精品永久免费网站| 三级毛片av免费| 欧美日韩中文字幕国产精品一区二区三区 | 日本欧美视频一区| 中文亚洲av片在线观看爽| 窝窝影院91人妻| 亚洲国产中文字幕在线视频| 国产成人精品久久二区二区91| 国产免费av片在线观看野外av| 夜夜看夜夜爽夜夜摸| 亚洲国产日韩欧美精品在线观看 | 久久久久久免费高清国产稀缺| 91九色精品人成在线观看| 淫妇啪啪啪对白视频| 久久性视频一级片| 亚洲性夜色夜夜综合| 嫩草影院精品99| 琪琪午夜伦伦电影理论片6080| 亚洲精品粉嫩美女一区| 亚洲精品粉嫩美女一区| 国产欧美日韩精品亚洲av| 国产av一区二区精品久久| 男女下面进入的视频免费午夜 | 日日爽夜夜爽网站| 国产极品粉嫩免费观看在线| 18禁美女被吸乳视频| 午夜福利欧美成人| 欧美在线黄色| 好男人电影高清在线观看| 国产成人欧美| 一级毛片高清免费大全| 午夜成年电影在线免费观看| 亚洲免费av在线视频| 如日韩欧美国产精品一区二区三区| 最近最新中文字幕大全免费视频| 亚洲狠狠婷婷综合久久图片| 99国产精品免费福利视频| 一区福利在线观看| 亚洲成人精品中文字幕电影| 悠悠久久av| 国产视频一区二区在线看| 亚洲国产欧美网| 成人欧美大片| av天堂久久9| www.精华液| 精品欧美一区二区三区在线| 国产极品粉嫩免费观看在线| 高清毛片免费观看视频网站| 国产亚洲欧美在线一区二区| 人人妻人人爽人人添夜夜欢视频| 在线观看免费视频网站a站| 欧美激情 高清一区二区三区| 宅男免费午夜| 欧美老熟妇乱子伦牲交| 99热只有精品国产| 深夜精品福利| 久久久水蜜桃国产精品网| 男女床上黄色一级片免费看| 国产一区二区三区在线臀色熟女| 在线天堂中文资源库| 成人亚洲精品一区在线观看| 亚洲无线在线观看| 美女高潮喷水抽搐中文字幕| 欧美老熟妇乱子伦牲交| 18禁国产床啪视频网站| 久久精品国产清高在天天线| 黄色女人牲交| avwww免费| 日本 av在线| 一进一出好大好爽视频| 日韩欧美三级三区| 在线免费观看的www视频| 日韩欧美三级三区| 国产三级黄色录像| 欧美日韩中文字幕国产精品一区二区三区 | 亚洲av五月六月丁香网| 老熟妇乱子伦视频在线观看| 变态另类成人亚洲欧美熟女 | 亚洲成av片中文字幕在线观看| 琪琪午夜伦伦电影理论片6080| 久久人妻福利社区极品人妻图片| 亚洲第一青青草原| 久久中文看片网| 91成年电影在线观看| 视频区欧美日本亚洲| 欧美成人性av电影在线观看| 麻豆av在线久日| 亚洲国产精品成人综合色| 久久天躁狠狠躁夜夜2o2o| 黄色片一级片一级黄色片| av在线天堂中文字幕| 精品一品国产午夜福利视频| 亚洲五月色婷婷综合| 在线观看66精品国产| 亚洲专区字幕在线| 欧美国产精品va在线观看不卡| 91在线观看av| 亚洲av五月六月丁香网| 亚洲国产高清在线一区二区三 | 别揉我奶头~嗯~啊~动态视频| 青草久久国产| 欧美乱妇无乱码| 两性夫妻黄色片| 免费看十八禁软件| 两个人视频免费观看高清| 日日干狠狠操夜夜爽| 国产精品久久久久久人妻精品电影| 亚洲精品久久国产高清桃花| 十八禁人妻一区二区| 好男人在线观看高清免费视频 | 国产一区二区激情短视频| 亚洲精品美女久久久久99蜜臀| 日韩欧美一区二区三区在线观看| 巨乳人妻的诱惑在线观看| avwww免费| 美女高潮喷水抽搐中文字幕| 国产精品二区激情视频| 少妇裸体淫交视频免费看高清 | 国产精品美女特级片免费视频播放器 | 久久久水蜜桃国产精品网| 久久中文看片网| 在线免费观看的www视频| av视频免费观看在线观看| 一区二区日韩欧美中文字幕| 国产91精品成人一区二区三区| 亚洲精品在线观看二区| 波多野结衣高清无吗| 国产男靠女视频免费网站| av天堂在线播放| 黑人巨大精品欧美一区二区蜜桃| 999久久久精品免费观看国产| 国产亚洲精品久久久久久毛片| 亚洲熟女毛片儿| 在线观看免费视频日本深夜| 丝袜在线中文字幕| 亚洲成人久久性| 一进一出抽搐gif免费好疼| 一区二区三区高清视频在线| 日本免费一区二区三区高清不卡 | 一夜夜www| 老鸭窝网址在线观看| 香蕉国产在线看| 大码成人一级视频| 亚洲情色 制服丝袜| 国产精品电影一区二区三区| 人人澡人人妻人| 757午夜福利合集在线观看| 亚洲一区二区三区色噜噜| 久久久国产欧美日韩av| 他把我摸到了高潮在线观看| 国产私拍福利视频在线观看| 成人免费观看视频高清| av在线天堂中文字幕| 色播亚洲综合网| 欧美日韩福利视频一区二区| av天堂久久9| 波多野结衣巨乳人妻| 又黄又爽又免费观看的视频| 日本免费一区二区三区高清不卡 | 母亲3免费完整高清在线观看| 久久九九热精品免费| 好男人在线观看高清免费视频 | 后天国语完整版免费观看| 国产精品 欧美亚洲| svipshipincom国产片| 亚洲 欧美一区二区三区| 国产亚洲精品一区二区www| 又黄又爽又免费观看的视频| 黄网站色视频无遮挡免费观看| 欧美+亚洲+日韩+国产| avwww免费| 人人妻人人爽人人添夜夜欢视频| 88av欧美| 女生性感内裤真人,穿戴方法视频| 国产精品精品国产色婷婷| 99riav亚洲国产免费| 亚洲成国产人片在线观看| 日韩大尺度精品在线看网址 | 搡老岳熟女国产| 88av欧美| 高清黄色对白视频在线免费看| 国产国语露脸激情在线看| 色av中文字幕| 精品国产乱子伦一区二区三区| 一二三四在线观看免费中文在| 美女扒开内裤让男人捅视频| 中文字幕最新亚洲高清| 久久久久久久久中文| 女同久久另类99精品国产91| 久久人人精品亚洲av| 99国产精品免费福利视频| 最近最新中文字幕大全免费视频| 国产国语露脸激情在线看| 久久精品国产99精品国产亚洲性色 | 制服丝袜大香蕉在线| 国产成人精品无人区| 免费在线观看黄色视频的| 日韩欧美国产在线观看| 色婷婷久久久亚洲欧美| 少妇粗大呻吟视频| 他把我摸到了高潮在线观看| 老鸭窝网址在线观看| 好男人在线观看高清免费视频 | 国产欧美日韩一区二区精品| 欧美中文日本在线观看视频| 国产精品一区二区免费欧美| 一本大道久久a久久精品| 一边摸一边做爽爽视频免费| 在线视频色国产色| 久久精品影院6| 18美女黄网站色大片免费观看| 精品无人区乱码1区二区| 久久伊人香网站| 女人爽到高潮嗷嗷叫在线视频| 精品国产亚洲在线| 涩涩av久久男人的天堂| 日韩欧美一区二区三区在线观看| 黄频高清免费视频| 热99re8久久精品国产| www.熟女人妻精品国产| 手机成人av网站| 不卡一级毛片| 在线视频色国产色| 丝袜美腿诱惑在线| 国产精品秋霞免费鲁丝片| 日本在线视频免费播放| 成年版毛片免费区| av欧美777| 两个人视频免费观看高清| 久久这里只有精品19| 久久热在线av| 美女国产高潮福利片在线看| 中文字幕人成人乱码亚洲影| 十八禁网站免费在线| 电影成人av| 久久精品国产99精品国产亚洲性色 | 成人国语在线视频| 午夜日韩欧美国产| 少妇粗大呻吟视频| 国产精品日韩av在线免费观看 | 亚洲三区欧美一区| 久久精品国产亚洲av香蕉五月| 色播亚洲综合网| 亚洲欧美精品综合久久99| 中文字幕精品免费在线观看视频| 老熟妇仑乱视频hdxx| 亚洲熟妇中文字幕五十中出| 中文字幕另类日韩欧美亚洲嫩草| 国产精品秋霞免费鲁丝片| 久久国产亚洲av麻豆专区| 亚洲色图av天堂| 国产真人三级小视频在线观看| 中文字幕另类日韩欧美亚洲嫩草| 国产成人一区二区三区免费视频网站| 久久久久久久久免费视频了| 97人妻天天添夜夜摸| 久久久久亚洲av毛片大全| 国产精品九九99| 青草久久国产| 亚洲天堂国产精品一区在线| 免费无遮挡裸体视频| 日韩欧美一区视频在线观看| 亚洲aⅴ乱码一区二区在线播放 | 又黄又粗又硬又大视频| 91字幕亚洲| 国产精品免费一区二区三区在线| cao死你这个sao货| 女人被狂操c到高潮| 国产亚洲精品综合一区在线观看 | 99riav亚洲国产免费| 久久伊人香网站| 999久久久精品免费观看国产| 深夜精品福利| 亚洲色图 男人天堂 中文字幕| 日韩大尺度精品在线看网址 | 久久香蕉激情| 一级毛片高清免费大全| 婷婷精品国产亚洲av在线| 琪琪午夜伦伦电影理论片6080| 午夜精品在线福利| 久久人妻av系列| 一级黄色大片毛片| 精品人妻在线不人妻| 男女之事视频高清在线观看| 免费在线观看亚洲国产| 久久人人爽av亚洲精品天堂| 欧美激情久久久久久爽电影 | 18禁裸乳无遮挡免费网站照片 | 极品教师在线免费播放| 18禁黄网站禁片午夜丰满| 精品卡一卡二卡四卡免费| ponron亚洲| 中文字幕人妻丝袜一区二区| 视频在线观看一区二区三区| 在线观看免费日韩欧美大片| av福利片在线| 欧美最黄视频在线播放免费| 国产亚洲av高清不卡| 美女午夜性视频免费| 欧美日韩乱码在线| 欧美色欧美亚洲另类二区 | 国产主播在线观看一区二区| 日韩欧美免费精品| 免费不卡黄色视频| 欧美日本视频| 亚洲av成人不卡在线观看播放网| 国产黄a三级三级三级人| 波多野结衣一区麻豆| 9色porny在线观看| 动漫黄色视频在线观看| 88av欧美| 午夜精品在线福利| 国产激情欧美一区二区| 欧美日韩黄片免| 99在线人妻在线中文字幕| 中文字幕人妻熟女乱码| 看片在线看免费视频| 亚洲精品一区av在线观看| 亚洲av第一区精品v没综合| www.熟女人妻精品国产| 国产午夜福利久久久久久| 国产一区二区三区在线臀色熟女| 婷婷丁香在线五月| 国产精品免费视频内射| 啦啦啦 在线观看视频| 成年女人毛片免费观看观看9| 97人妻天天添夜夜摸| 长腿黑丝高跟| 日本vs欧美在线观看视频| 一本综合久久免费| 一a级毛片在线观看| 一级,二级,三级黄色视频| 久久久久精品国产欧美久久久| 妹子高潮喷水视频| av有码第一页| 精品国产一区二区久久| 香蕉久久夜色| 国产真人三级小视频在线观看| 久久久久国内视频| 最新美女视频免费是黄的| 中文亚洲av片在线观看爽| 亚洲精品美女久久av网站| 午夜精品久久久久久毛片777| 最近最新中文字幕大全电影3 | av福利片在线| 欧美日本视频| 亚洲欧美日韩无卡精品| 国产精品av久久久久免费| 国产97色在线日韩免费| 午夜激情av网站| 99精品欧美一区二区三区四区| 18禁裸乳无遮挡免费网站照片 | 视频在线观看一区二区三区| 色尼玛亚洲综合影院| 妹子高潮喷水视频| 大陆偷拍与自拍| 精品日产1卡2卡| 欧美激情久久久久久爽电影 | 国产欧美日韩综合在线一区二区| 国产精品野战在线观看| 亚洲精品国产区一区二| 90打野战视频偷拍视频| 99久久国产精品久久久| 亚洲va日本ⅴa欧美va伊人久久| 日韩欧美一区视频在线观看| 青草久久国产| 一级毛片高清免费大全| 一进一出抽搐gif免费好疼| 黄色视频,在线免费观看| 亚洲第一欧美日韩一区二区三区| 成年版毛片免费区| 欧美黑人欧美精品刺激| 久久精品国产99精品国产亚洲性色 | 国产97色在线日韩免费| 一边摸一边抽搐一进一出视频| 久久婷婷人人爽人人干人人爱 | 亚洲三区欧美一区| 国产精品精品国产色婷婷| 亚洲欧美日韩高清在线视频| 18禁观看日本| 国产av精品麻豆| 亚洲男人的天堂狠狠| 黄网站色视频无遮挡免费观看| 变态另类丝袜制服| 国产亚洲欧美98| 国产精品一区二区精品视频观看| 99国产综合亚洲精品| 国产精华一区二区三区| 香蕉久久夜色| 亚洲精品美女久久久久99蜜臀| 成人国语在线视频| 动漫黄色视频在线观看| 欧美激情高清一区二区三区| 国产激情久久老熟女| 日本免费一区二区三区高清不卡 | 真人做人爱边吃奶动态| 精品乱码久久久久久99久播| 狂野欧美激情性xxxx| 老熟妇仑乱视频hdxx| av超薄肉色丝袜交足视频| 午夜日韩欧美国产| 亚洲精品久久成人aⅴ小说| av福利片在线| 亚洲av五月六月丁香网| 啦啦啦 在线观看视频| √禁漫天堂资源中文www| 丝袜在线中文字幕| 国内毛片毛片毛片毛片毛片| 在线国产一区二区在线| 在线av久久热| 嫩草影视91久久| 别揉我奶头~嗯~啊~动态视频| 黄色成人免费大全| 老鸭窝网址在线观看| 国产亚洲精品综合一区在线观看 | 欧美一级a爱片免费观看看 | 亚洲avbb在线观看| ponron亚洲| cao死你这个sao货| 窝窝影院91人妻| 欧美午夜高清在线| 性少妇av在线| 国产午夜福利久久久久久| 亚洲av电影在线进入| 国产av一区在线观看免费| 老熟妇仑乱视频hdxx| 欧美成人性av电影在线观看| 中文字幕高清在线视频| 在线永久观看黄色视频| 国产麻豆69| 悠悠久久av| 亚洲国产欧美一区二区综合| 丝袜美足系列| 岛国视频午夜一区免费看| 久久久久国产一级毛片高清牌| 国产午夜福利久久久久久| 久久精品国产亚洲av高清一级| 国产99久久九九免费精品| 久久亚洲精品不卡| 久久久久久亚洲精品国产蜜桃av| 国产欧美日韩一区二区三区在线| 久久久久久久精品吃奶| 国产精品野战在线观看| 日韩欧美一区视频在线观看| 精品一区二区三区四区五区乱码| 黑人巨大精品欧美一区二区mp4| av在线天堂中文字幕| 亚洲欧美日韩高清在线视频| 亚洲第一av免费看| 99在线视频只有这里精品首页| 手机成人av网站| 亚洲av电影在线进入| 国产在线精品亚洲第一网站| 波多野结衣av一区二区av| 国产欧美日韩一区二区精品| 手机成人av网站| 久久久精品欧美日韩精品| 久久热在线av| 啦啦啦免费观看视频1| 国产成人av教育| 黄色 视频免费看| 男人的好看免费观看在线视频 | 国产午夜精品久久久久久| 人人澡人人妻人| 久久婷婷人人爽人人干人人爱 | 黑人巨大精品欧美一区二区蜜桃| 黄片大片在线免费观看| 色老头精品视频在线观看| 久久中文字幕一级| 久久 成人 亚洲| 久久精品国产清高在天天线| 精品日产1卡2卡| 村上凉子中文字幕在线| 免费在线观看亚洲国产| 欧美一区二区精品小视频在线| 视频在线观看一区二区三区| 亚洲va日本ⅴa欧美va伊人久久| 啦啦啦 在线观看视频| www.熟女人妻精品国产| 波多野结衣高清无吗| 午夜免费激情av| 女同久久另类99精品国产91| 免费人成视频x8x8入口观看| 韩国av一区二区三区四区| 99精品欧美一区二区三区四区| 午夜福利成人在线免费观看| 无遮挡黄片免费观看| 人人妻人人澡人人看| 老熟妇仑乱视频hdxx| 香蕉国产在线看| 亚洲三区欧美一区| av网站免费在线观看视频| 搞女人的毛片| 亚洲无线在线观看| 欧美最黄视频在线播放免费| 国产精品二区激情视频| 久久热在线av| 长腿黑丝高跟| 一级毛片精品| 亚洲成av片中文字幕在线观看| svipshipincom国产片| 美女免费视频网站| 国产区一区二久久| 97碰自拍视频| 夜夜夜夜夜久久久久| 亚洲 欧美 日韩 在线 免费| 日韩高清综合在线| 侵犯人妻中文字幕一二三四区| 亚洲精品中文字幕一二三四区| 精品国产国语对白av| 成人免费观看视频高清| 精品国产乱子伦一区二区三区| 91麻豆精品激情在线观看国产| 亚洲av电影不卡..在线观看| 涩涩av久久男人的天堂| 极品人妻少妇av视频| 男人舔女人的私密视频| 久9热在线精品视频| 亚洲熟女毛片儿| 中国美女看黄片| 精品福利观看| 人成视频在线观看免费观看| 99国产精品一区二区三区| 久久中文字幕一级| 亚洲av成人一区二区三| 国产亚洲欧美在线一区二区| 国产99久久九九免费精品| 亚洲av美国av| 精品第一国产精品| 国产一卡二卡三卡精品| 日韩欧美在线二视频| 国产精品香港三级国产av潘金莲| 精品午夜福利视频在线观看一区| 精品人妻在线不人妻| av天堂久久9| 午夜免费观看网址| 亚洲欧洲精品一区二区精品久久久| 一进一出好大好爽视频| 久久久久久久久免费视频了| 亚洲久久久国产精品| 高潮久久久久久久久久久不卡| 99热只有精品国产| 午夜免费鲁丝| 亚洲久久久国产精品| 日日摸夜夜添夜夜添小说| 日韩视频一区二区在线观看| 国产伦一二天堂av在线观看| 69av精品久久久久久| 国产精品98久久久久久宅男小说| 一边摸一边抽搐一进一小说| 国产成人欧美| 国产成人av教育| 久久人人精品亚洲av| 成人亚洲精品av一区二区| 在线观看一区二区三区| 老司机福利观看| 午夜福利一区二区在线看| 久久人人爽av亚洲精品天堂| 变态另类丝袜制服| 中文字幕高清在线视频| 亚洲av电影在线进入| 亚洲专区字幕在线| 亚洲一码二码三码区别大吗| 午夜激情av网站| 久久精品成人免费网站| 妹子高潮喷水视频| 精品欧美国产一区二区三| 久久婷婷成人综合色麻豆| 操出白浆在线播放| 啦啦啦免费观看视频1|